Rosiglitazone (RSG), an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), regulates the transcription of multiple genes related to the effects of insulin and so significantly ameliorates insulin resistance and oxidative stress that helps lower the incidence of cardiovascular diseases in T2DM patients [8, 9]. Here, INS is linked to Insulin resistance.